



Executive summary of Outputs of Joint Working Agreement for the severe asthma pathway resource at Aneurin Bevan University Health Board (UHB)

Published on <https://www.astrazeneca.co.uk/partnerships/working-with-nhs>

Project title	Severe Asthma Pathway Resource
Duration	22 months
Project partners	Aneurin Bevan University Health Board (UHB) and AstraZeneca UK
What was the issue to be addressed?	Optimise the identification and management of Severe asthma in primary and secondary care
What were the results?	• The number of patients with severe asthma on biologics has increased from 117 to 408 patients over this time period which represents a 349% increase in patients. • Median time to confirmed asthma diagnosis has dropped from 21 weeks to 8.3 weeks • Median time to MDT discussion of patients for consideration of biologics has dropped from 43 days to 15 days • Median time from MDT to biologic initiation from 112 days to 13 days • 100% of patients are re-discussed at 1 year • 100% of patients rediscussed at 1 year after biologic initiation with 67% continuing, 21% switching and 12% discontinuing treatment